Jefferies analyst Martin Comtesse maintained a Buy rating on DocMorris today and set a price target of CHF12.00.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Martin Comtesse has given his Buy rating due to a combination of factors related to DocMorris’s earnings trajectory and guidance. The company’s 2025 EBITDA loss of CHF -50m is in line with the management’s original target range, which provides credibility to their planning and underpins confidence in the next phase of the turnaround.
Looking ahead to 2026, management is steering the business toward EBITDA break-even as the year unfolds, supported by guidance for adjusted EBITDA between CHF -10m and -25m, with the midpoint exceeding current consensus by a notable margin. Following another transition year with substantial external funding, DocMorris also anticipates external sales to grow at a mid-single- to low-teens percentage rate, signaling improving scale and operating leverage that justify the positive rating.